unsplash-image-u0TsofR4rH4.jpg

Technology that connects, innovation that cares

For lowering bad cholesterol by AstraZeneca

‘AZURE-Outcomes Study’

  • The AZURE-Outcomes study is a large research project (Phase III) that aims to see if a new medicine, AZD0780, can help reduce serious heart and blood vessel problems in people. These problems include heart attacks, strokes, and other issues related to narrowed arteries. The study will compare AZD0780 with a placebo (a dummy pill) to see if it makes a difference.

  • AZD0780 is a type of medicine called an oral PCSK9 inhibitor. PCSK9 is a protein in the body that plays a role in how much "bad" cholesterol (LDL-C) is in your blood. By blocking PCSK9, AZD0780 is designed to lower LDL-C levels, which in turn is expected to reduce the risk of heart and blood vessel problems.

  • Statins and other medicines help manage LDL cholesterol, but some people still have high levels and risk of heart attack or stroke. PCSK9 inhibitors lower LDL but currently require injections, which can be inconvenient. This study tests AZD0780, an ‘oral’ PCSK9 inhibitor, to see if it reduces LDL and cardiovascular risks.

    • Birmingham B21 9RY

    • Bristol BS105NB

    • Calow S44 5BL

    • Chippenham SN15 2SB

    • Congleton CW12 1JP

    • Dundee DD1 9SY

    • Enfield EN1 3LL

    • Gateshead NE9 6SX

    • Glasgow G20 7BE

    • Harefield UB9 6JH

    • Kings Lynn PE30 4ET

    • London EC1M 6BQ

    • London N20 9EX

    • London NW3 2QG

    • London SW10 9NH

    • Metropolitan Borough of Wirral CH62 6EE

    • Middlesex HA5 4EA

    • Milton Keynes MK6 5LD

    • Newcastle upon Tyne NE1 4LP

    • Poole BH16 5PW

    • Sheffield S5 7AU

    • Wakefield WF1 4DG

    • West Bromwich B71 4HJ

    • Yeovil BA21 4AT

  • https://clinicaltrials.gov/study/NCT07000357

Chat with AI agent to check eligibility

‘MOVE-Lp(a) study’

For lowering bad cholesterol by Eli Lilly

  • The MOVE-Lp(a) study is a Phase 3 clinical trial designed to assess how well a drug called muvalaplin (also known as LY3473329) can reduce the risk of major heart-related problems in adults. These adults either have high levels of a type of fat in their blood called lipoprotein(a) and have already experienced a heart event, or they are at high risk of having a first heart event.

    The main goal is to see if muvalaplin can delay or prevent serious cardiovascular events like heart attack, stroke, or urgent procedures to restore blood flow to the heart. The study will compare muvalaplin to a placebo (a substance with no active drug) to understand its effectiveness.

  • The investigational drug, muvalaplin, is a medication administered orally. Its purpose is to reduce cardiovascular risk in individuals with elevated lipoprotein(a).

  • There is currently no medicine to lower lipoprotein(a) levels, except for lipoprotein apheresis, a dialysis-like treatment, and some medicines still being tested.

  • Belfast BT16 1RH

    Blackpool FY3 7EN

    Bodelwyddan LL18 5UJ

    Bradford-on-Avon BA15 1DQ

    Bristol BS2 8HW

    Enfield EN3 4GS

    Glasgow G20 7BE

    High Wycombe HP11 2QW

    Hounslow TW4 7NR

    Inverness IV2 3UJ

    Liskeard PL14 3XA

    London NW10 2PB

    Poole BH16 5PW

    Preston PR2 9QB

    Rochdale OL11 4AU

    Sheffield S2 5FX

    Stockton-on-Tees TS19 8PE

    Torpoint PL11 2TB

    West Bromwich B71 4HJ

    York YO24 4LJ

  • https://clinicaltrials.gov/study/NCT07157774

Chat with AI agent to check eligibility

‘EASi-HF Preserved study’

For treating heart failure by Boehringer Ingelheim

  • The EASi-HF Reduced study (NCT06935370) is a research study for adults with chronic heart failure who have a reduced pumping function of the left side of their heart. The main goal is to see if a medicine called vicadrostat, when given along with another medicine called empagliflozin, helps people with this condition.

    Participants in the study are randomly assigned to one of two groups. One group receives vicadrostat/empagliflozin tablets. The other group receives placebo (a tablet with no medicine) / empagliflozin tablets.

    The study medicines are taken once a day for up to about 3.5 years, during which participants continue their usual heart failure treatment. Doctors monitor participants' health, including any worsening of heart failure symptoms, hospitalizations due to heart failure, or death, to compare the effectiveness of the treatments.

  • The investigational drug in this study is vicadrostat. It is being tested in combination with empagliflozin to see if this combination helps people with chronic heart failure and a weak left ventricular pumping function. The specific mechanism of how vicadrostat works in this context is being evaluated during the study. Empagliflozin is also a medication used in heart failure treatment.

  • Medications called finerenone or spironolactone (mineralocorticoid receptor antagonists) are available and act in a similar way. However, vicadrostat (aldosterone synthase inhibitor) may offer a more targeted approach.

    • Bristol BS10 5NB

    • Exeter EX2 5DW

    • Halifax HX3 0PW

    • London EC1A 7BE

  • https://clinicaltrials.gov/study/NCT06935370

Chat with AI agent to check eligibility

‘EASi-HF Reduced study’

For treating heart failure by Boehringer Ingelheim

  • The EASi-HF Preserved study is a large research project involving approximately 6,000 adults aged 18 or older who have heart failure. Specifically, participants have symptoms of heart failure and a left ventricular ejection fraction (LVEF) of 40% or more. The main goal of this study is to determine if a new combination treatment, consisting of vicadrostat (also known as BI 690517) and empagliflozin, is more effective and safer than empagliflozin alone (with a placebo instead of vicadrostat) in managing heart failure.

    Participants are randomly assigned to one of two groups.

    Vicadrostat/empagliflozin group: Participants in this group take tablets containing both vicadrostat and empagliflozin once a day.

    Placebo/empagliflozin group: Participants in this group take empagliflozin tablets once a day, along with a placebo tablet that looks like vicadrostat but contains no active drug.

  • The investigational drug in this study is vicadrostat. It is being tested in combination with empagliflozin to see if this combination helps people with chronic heart failure and a weak left ventricular pumping function. The specific mechanism of how vicadrostat works in this context is being evaluated during the study. Empagliflozin is also a medication used in heart failure treatment.

  • Medications called finerenone or spironolactone (mineralocorticoid receptor antagonists) are available and act in a similar way. However, vicadrostat (aldosterone synthase inhibitor) may offer a more targeted approach.

    • Barnet EN5 3DJ

    • Bristol BS10 5NB

    • Liverpool L14 3PE

    • Exeter EX2 5DW

    • Halifax HX3 0PW

    • London EC1A 7BE

    • Oldham OL1 2JH

    • Sheffield S5 7AU

    • Truro TR1 3LJ

    • York YO31 8HE

  • https://clinicaltrials.gov/study/NCT06935370

Chat with AI agent to check eligibility

‘Prevent-HF study’

For treating heart failure by AstraZeneca

  • The Prevent-HF study is a Phase III research study that aims to determine if a new drug called baxdrostat, when used together with an existing medication called dapagliflozin, can reduce the risk of developing heart failure and cardiovascular death. The study will compare this combination treatment with dapagliflozin alone.

  • The investigational drug is called baxdrostat. It is being studied to see if it can help prevent heart failure and cardiovascular death in people who are at a higher risk. In this study, baxdrostat will be given in combination with dapagliflozin, a medication already used to treat type 2 diabetes and heart failure.

  • Medications called finerenone or spironolactone (mineralocorticoid receptor antagonists) are available and act in a similar way. However, baxdrostat (aldosterone synthase inhibitor) may offer a more targeted approach.

    • Aberdeen AB25 2ZN

    • Chesterfield S40 4AA

    • Dundee DD1 9SY

    • Glasgow G31 2ER

    • Glasgow G51 4TF

    • London E11BB

    • Norwich NR128DU

    • Penzance TR18 3DX

    • Sandbach CW11 1EQ

    • Swansea SA6 6NL

    • Weston-super-Mare BS24 7PR

    • Wolverhampton WV10 0QP

    • Woodbridge IP136TH

    • Yate BS37 4AX

  • https://clinicaltrials.gov/study/NCT06677060

Chat with AI agent to check eligibility